PureTech Health plc (PTCHF)
USD 1.75
(-5.91%)
USD 1.75
(-5.91%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.6 Million USD | 98.93% |
| 2022 | -150.34 Million USD | -49.61% |
| 2021 | -100.49 Million USD | -1304.8% |
| 2020 | 8.34 Million USD | 110.81% |
| 2019 | -77.16 Million USD | -26.43% |
| 2018 | -61.03 Million USD | 13.29% |
| 2017 | -70.38 Million USD | -2560.15% |
| 2016 | 2.86 Million USD | -73.99% |
| 2015 | 11 Million USD | 446.72% |
| 2014 | 2.01 Million USD | -71.33% |
| 2013 | 7.01 Million USD | -11.51% |
| 2012 | 7.93 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -19.32 Million USD | 0.0% |
| 2024 Q1 | -19.32 Million USD | -1050.99% |
| 2023 Q2 | 89 Thousand USD | 100.36% |
| 2023 Q1 | -24.99 Million USD | -0.32% |
| 2023 FY | -1.6 Million USD | 98.93% |
| 2023 Q4 | -1.67 Million USD | 92.18% |
| 2023 Q3 | -21.45 Million USD | -24206.18% |
| 2022 Q4 | -24.91 Million USD | 15.91% |
| 2022 Q2 | -35.25 Million USD | 9.06% |
| 2022 Q3 | -29.63 Million USD | 15.96% |
| 2022 FY | -150.34 Million USD | -49.61% |
| 2022 Q1 | -38.77 Million USD | 48.06% |
| 2021 FY | -100.49 Million USD | -1304.8% |
| 2021 Q2 | -18.32 Million USD | 13.73% |
| 2021 Q4 | -74.64 Million USD | -305.93% |
| 2021 Q3 | -18.38 Million USD | -0.33% |
| 2021 Q1 | -21.24 Million USD | -48.69% |
| 2020 FY | 8.34 Million USD | 110.81% |
| 2020 Q2 | -15.7 Million USD | 0.0% |
| 2020 Q3 | -16.66 Million USD | -6.11% |
| 2020 Q4 | -14.28 Million USD | 14.25% |
| 2020 Q1 | -15.7 Million USD | 73.91% |
| 2019 FY | -77.16 Million USD | -26.43% |
| 2019 Q3 | -17.46 Million USD | 4.93% |
| 2019 Q4 | -60.18 Million USD | -244.69% |
| 2019 Q2 | -18.36 Million USD | 10.67% |
| 2019 Q1 | -20.56 Million USD | -44.93% |
| 2018 Q4 | -14.18 Million USD | 0.0% |
| 2018 FY | -61.03 Million USD | 13.29% |
| 2018 Q2 | -14.14 Million USD | 0.0% |
| 2018 Q1 | -14.14 Million USD | 17.37% |
| 2018 Q3 | -14.18 Million USD | -0.33% |
| 2017 Q3 | -17.11 Million USD | 0.13% |
| 2017 Q1 | -17.13 Million USD | 7.42% |
| 2017 Q2 | -17.13 Million USD | 0.0% |
| 2017 FY | -70.38 Million USD | -2560.15% |
| 2017 Q4 | -17.11 Million USD | 0.0% |
| 2016 Q2 | 121.5 Thousand USD | 0.0% |
| 2016 FY | 2.86 Million USD | -73.99% |
| 2016 Q1 | 121.5 Thousand USD | -71.04% |
| 2016 Q4 | -18.5 Million USD | 0.0% |
| 2016 Q3 | -18.5 Million USD | -15333.33% |
| 2015 Q3 | 419.5 Thousand USD | -92.37% |
| 2015 Q1 | 5.49 Million USD | 915.62% |
| 2015 FY | 11 Million USD | 446.72% |
| 2015 Q4 | 419.5 Thousand USD | 0.0% |
| 2015 Q2 | 5.49 Million USD | 0.0% |
| 2014 Q2 | 570 Thousand USD | 0.0% |
| 2014 Q4 | 541 Thousand USD | 0.0% |
| 2014 Q1 | 570 Thousand USD | 0.0% |
| 2014 FY | 2.01 Million USD | -71.33% |
| 2014 Q3 | 541 Thousand USD | -5.09% |
| 2013 FY | 7.01 Million USD | -11.51% |
| 2012 FY | 7.93 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -65623.657% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 113.694% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -401.71% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 101.346% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 93.786% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -3221.66% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -1190.13% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 110.687% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 51776.338% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 116.367% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 2538.839% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -4593.997% |
| Mesoblast Limited | -35.16 Million USD | 95.442% |
| Marizyme, Inc. | 457.7 Thousand USD | 450.228% |
| Genus plc | 178.7 Million USD | 100.897% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.728% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 2676.094% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 490.818% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -14472.727% |
| ContraFect Corporation | -154 Thousand USD | -940.909% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -3106.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 2188.3% |
| IMV Inc. | -962.29 Thousand USD | -66.58% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -313.676% |
| MultiCell Technologies, Inc. | 49.32 USD | 3250302.758% |
| ONE Bio Corp. | 20.12 Million USD | 107.965% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 103.981% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 3378.119% |
| Q BioMed Inc. | -8988.00 USD | -17734.891% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 105.673% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -10292.894% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 103.614% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -40.42% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 2390.0% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -32270.759% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 1240.925% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -1543.85% |
| GB Sciences, Inc. | -624.00 USD | -256791.026% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -1763.347% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.021% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -770573.077% |
| Enzolytics Inc. | 30.7 Thousand USD | 5320.138% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 432.274% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.145% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -211.559% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 359.644% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.391% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -18000.723% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -1811.77% |
| Kadimastem Ltd | -630.13 Thousand USD | -154.389% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 262.25% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 116.679% |
| BioStem Technologies, Inc. | 15.42 Million USD | 110.392% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -13444.571% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1007.907% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1007.907% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 218.116% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -5427.586% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 456.188% |
| SYBLEU INC | 11.69 Thousand USD | 13805.54% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 134.787% |
| Bioxytran, Inc. | -8285.00 USD | -19248.22% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -329.759% |
| Neutra Corp. | 14.33 Thousand USD | 11282.421% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -1854.878% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -60.102% |
| IXICO plc | 3.27 Million USD | 149.021% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -130.98% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 10.497% |
| CSL Limited | 7.7 Billion USD | 100.021% |
| Cellectis S.A. | 18 Thousand USD | 9005.556% |